기준가
$99.12
운용 규모
$77.9M
보수율
-
배당수익률
0.00%
베타
0.79
통화
USD
| YTD | 1개월 | 3개월 | 1년 | 3년 | 5년 |
|---|---|---|---|---|---|
| +23.98% | +16.96% | +18.37% | +65.86% | +23.54% | +13.04% |
| 순위 | 종목코드 | 종목명 | 비중 |
|---|---|---|---|
| 1 | IBRX | ImmunityBio Inc Ordinary Shares | 5.11% |
| 2 | IOVA | Iovance Biotherapeutics Inc | 2.99% |
| 3 | NVAX | Novavax Inc | 2.68% |
| 4 | MRNA | Moderna Inc | 2.57% |
| 5 | KALV | KalVista Pharmaceuticals Inc | 2.55% |
| 6 | AXSM | Axsome Therapeutics Inc | 2.54% |
| 7 | MIRM | Mirum Pharmaceuticals Inc | 2.50% |
| 8 | ROIV | Roivant Sciences Ltd Ordinary Shares | 2.18% |
| 9 | TVTX | Travere Therapeutics Inc Ordinary Shares | 2.17% |
| 10 | KRYS | Krystal Biotech Inc | 2.03% |
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.
설정일: 2014-12-16